1 | technical storage or access | | | | | | | 5 | 0.97% |
2 | storage or access is | | | | | | | 3 | 0.58% |
3 | the subscriber or user | | | | | | | 2 | 0.39% |
4 | team list prof dr | | | | | | | 2 | 0.39% |
5 | storage or access that | | | | | | | 2 | 0.39% |
6 | or access that is | | | | | | | 2 | 0.39% |
7 | access that is used | | | | | | | 2 | 0.39% |
8 | hemorrhagic fever viruses projects | | | | | | | 2 | 0.39% |
9 | that is used exclusively | | | | | | | 2 | 0.39% |
10 | is used exclusively for | | | | | | | 2 | 0.39% |
11 | papillomavirus influenza a virus | | | | | | | 2 | 0.39% |
12 | mproteinmediated infectivity tikoco covaco | | | | | | | 2 | 0.39% |
13 | policy cookie policy eu | | | | | | | 2 | 0.39% |
14 | human cytomegalovirus coronaviruses human | | | | | | | 2 | 0.39% |
15 | team team list prof | | | | | | | 2 | 0.39% |
16 | list prof dr ralf | | | | | | | 2 | 0.39% |
17 | the technical storage or | | | | | | | 2 | 0.39% |
18 | necessary for the legitimate | | | | | | | 2 | 0.39% |
19 | by the subscriber or | | | | | | | 2 | 0.39% |
20 | prof dr ralf wagner | | | | | | | 2 | 0.39% |
21 | hivactogc nanoneutvir ehva hfvac3 | | | | | | | 2 | 0.39% |
22 | dr ralf wagner open | | | | | | | 2 | 0.39% |
23 | information consenting to these | | | | | | | 1 | 0.19% |
24 | consenting to these technologies | | | | | | | 1 | 0.19% |
25 | to these technologies will | | | | | | | 1 | 0.19% |
26 | these technologies will allow | | | | | | | 1 | 0.19% |
27 | cookies to store andor | | | | | | | 1 | 0.19% |
28 | technologies will allow us | | | | | | | 1 | 0.19% |
29 | device information consenting to | | | | | | | 1 | 0.19% |
30 | like cookies to store | | | | | | | 1 | 0.19% |
31 | technologies like cookies to | | | | | | | 1 | 0.19% |
32 | will allow us to | | | | | | | 1 | 0.19% |
33 | use technologies like cookies | | | | | | | 1 | 0.19% |
34 | we use technologies like | | | | | | | 1 | 0.19% |
35 | to store andor access | | | | | | | 1 | 0.19% |
36 | browsing behaviour or unique | | | | | | | 1 | 0.19% |
37 | process data such as | | | | | | | 1 | 0.19% |
38 | may adversely affect certain | | | | | | | 1 | 0.19% |
39 | the legitimate purpose of | | | | | | | 1 | 0.19% |
40 | for the legitimate purpose | | | | | | | 1 | 0.19% |